肝细胞癌肝移植术后免疫抑制剂的应用

杨扬; 邓宜南

doi:10.3969/j.issn.1001-5256.2021.02.005

肝细胞癌肝移植术后免疫抑制剂的应用

DOI: 10.3969/j.issn.1001-5256.2021.02.005

杨扬^,,
邓宜南

中山大学附属第三医院肝移植中心，广州 510630

作者贡献声明：邓宜南负责整理论文资料；杨扬负责起草论文、修订论文及终审论文。

详细信息

作者简介:
杨扬(1971—)，男，主任医师，博士，主要从事肝移植研究

通信作者:
杨扬，yysysu@163.com

中图分类号: R735.7;R617
计量
- 文章访问数: 737
- HTML全文浏览量: 206
- PDF下载量: 60
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-13
- 录用日期: 2021-01-04
- 出版日期: 2021-02-20

Application of immunosuppressants after liver transplantation for hepatocellular carcinoma

Yang YANG^,,
Yinan DENG

Center of Liver Transplantation, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China

摘要

摘要: 肝移植已经成为肝细胞癌根治性治疗的重要手段，但术后复发与转移严重限制了肝细胞癌肝移植的疗效。近年来，国内外学者围绕肝移植术后免疫抑制剂的应用与肝细胞癌复发转移的关系进行了一系列研究。现就肝细胞癌肝移植术后免疫抑制剂的临床应用策略及建议作一简述，以更好地指导临床。
- 癌, 肝细胞 /
- 肝移植 /
- 免疫抑制剂 /
- 移植物排斥 /
Abstract: Liver transplantation has become an important method for radical treatment of hepatocellular carcinoma (HCC), but postoperative recurrence and metastasis severely limit the efficacy of liver transplantation for HCC. In recent years, scholars in China and globally have conducted a series of studies on the association of the application of immunosuppressants after liver transplantation with the recurrence and metastasis of HCC. This article briefly introduces the strategies and suggestions for the clinical application of immunosuppressants after liver transplantation for HCC, in order to provide guidance for clinical practice.
- Carcinoma, Hepatocellular /
- Liver Transplantation /
- Immunosuppressive Agents /
- Graft Rejection /
- Neoplasm Recurrence, Local

HTML全文

参考文献(29)

[1]	VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. DOI: 10.1056/NEJMra1713263
[2]	ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1
[3]	MCGLYNN KA, PETRICK JL, LONDON WT. Global epidemiology of hepatocellular carcinoma: An emphasis on demographic and regional variability[J]. Clin Liver Dis, 2015, 19(2): 223-238. DOI: 10.1016/j.cld.2015.01.001
[4]	Organ Transplantation Branch, Chinese Medical Doctor Association; Chinese Society of Organ Transplantation, Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.02.008 中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008
[5]	RIZVI S, WANG J, EL-KHOUEIRY AB. Liver cancer immunity[J]. Hepatology, 2020. [Epub ahead of print]
[6]	PARDEE AD, BUTTERFIELD LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities[J]. Oncoimmunology, 2012, 1(1): 48-55. DOI: 10.4161/onci.1.1.18344
[7]	PRIETO J, MELERO I, SANGRO B. Immunological landscape and immunotherapy of hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(12): 681-700. DOI: 10.1038/nrgastro.2015.173
[8]	THOMSON AW, KNOLLE PA. Antigen-presenting cell function in the tolerogenic liver environment[J]. Nat Rev Immunol, 2010, 10(11): 753-766. DOI: 10.1038/nri2858
[9]	ZHONG M, ZHONG C, CUI W, et al. Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-Ⅰ-deficient stemness-high human liver cancer cells[J]. BMC Cancer, 2019, 19(1): 439. DOI: 10.1186/s12885-019-5670-9
[10]	CHENG JW, SHI YH, FAN J, et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2011, 137(10): 1445-1453. DOI: 10.1007/s00432-011-1014-0
[11]	RODRIGO E, LÓPEZ-HOYOS M, CORRAL M, et al. ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: A systematic review and meta-analysis[J]. Liver Transpl, 2012, 18(10): 1245-1253.
[12]	LIU F, XU L, SHENG C, et al. Optimization and application of an HPLC method for quantification of inosine-5'-monophosphate dehydrogenase activity as a pharmacodynamic biomarker of mycophenolic acid in Chinese renal transplant patients[J]. Clin Chim Acta, 2018, 485: 333-339. DOI: 10.1016/j.cca.2018.06.042
[13]	CHAE MS, KIM JW, CHUNG HS, et al. The impact of serum cytokines in the development of early allograft dysfunction in living donor liver transplantation[J]. Medicine (Baltimore), 2018, 97(16): e0400. DOI: 10.1097/MD.0000000000010400
[14]	RODRÍGUEZ-PERÁLVAREZ M, TSOCHATZIS E, NAVEAS MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6): 1193-1199. DOI: 10.1016/j.jhep.2013.07.012
[15]	LERUT J, IESARI S, FOGUENNE M, et al. Hepatocellular cancer and recurrence after liver transplantation: What about the impact of immunosuppression?[J]. Transl Gastroenterol Hepatol, 2017, 2: 80. DOI: 10.21037/tgh.2017.09.06
[16]	ZHOU J, FAN J, WANG Z, et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience[J]. World J Gastroenterol, 2006, 12(19): 3114-3118. DOI: 10.3748/wjg.v12.i19.3114
[17]	YANIK EL, CHINNAKOTLA S, GUSTAFSON SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl, 2016, 22(5): 627-634. DOI: 10.1002/lt.24395
[18]	THORAT A, JENG LB, YANG HR, et al. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: Re-inventing the role of mammalian target of rapamycin inhibitors[J]. Ann Hepatobiliary Pancreat Surg, 2017, 21(4): 205-211. DOI: 10.14701/ahbps.2017.21.4.205
[19]	JENG LB, LEE SG, SOIN AS, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study[J]. Am J Transplant, 2018, 18(6): 1435-1446. DOI: 10.1111/ajt.14623
[20]	GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10): 1260-1273. DOI: 10.1111/apt.15253
[21]	CHEN K, SHENG J, MA B, et al. Suppression of hepatocellular carcinoma by mycophenolic acid in experimental models and in patients[J]. Transplantation, 2019, 103(5): 929-937. DOI: 10.1097/TP.0000000000002647
[22]	CHEN ZS, HE F, ZENG FJ, et al. Early steroid withdrawal after liver transplantation for hepatocellular carcinoma[J]. World J Gastroenterol, 2007, 13(39): 5273-5276. DOI: 10.3748/wjg.v13.i39.5273
[23]	Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese standard for diagnosis and treatment of immunosuppressive therapy and rejection in liver transplantation (2019 Edition)[J/CD]. Chin J Transplant(Electronic Edition), 2019, 13(4): 262-268. (in Chinese) 中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 262-268.
[24]	GVNDISCH S, BOECKELER E, BEHRENDS U, et al. Glucocorticoids augment survival and proliferation of tumor cells[J]. Anticancer Res, 2012, 32(10): 4251-4261.
[25]	WEI Q, XU X, WANG C, et al. Efficacy and safety of a steroid-free immunosuppressive regimen after liver transplantation for hepatocellular carcinoma[J]. Gut Liver, 2016, 10(4): 604-610. DOI: 10.5009/gnl15017
[26]	WEI Q, GAO F, ZHUANG R, et al. A national report from China Liver Transplant Registry: Steroid avoidance after liver transplantation for hepatocellular carcinoma[J]. Chin J Cancer Res, 2017, 29(5): 426-437. DOI: 10.21147/j.issn.1000-9604.2017.05.07
[27]	DOHERTY DG. Immunity, tolerance and autoimmunity in the liver: A comprehensive review[J]. J Autoimmun, 2016, 66: 60-75.
[28]	SHI M, LIU Z, WANG Y, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection[J]. Stem Cells Transl Med, 2017, 6(12): 2053-2061. DOI: 10.1002/sctm.17-0134
[29]	LI S, ZHENG X, LI H, et al. Mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injury via inhibition of neutrophil recruitment[J]. J Immunol Res, 2018, 2018: 7283703.